• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BIA comments on Fresh Start report

BIA comments on Fresh Start report

January 17, 2014
CenterWatch Staff

Commenting on the Fresh Start report on the E.U. impact on the U.K. life science sector, Steve Bates, CEO of the BioIndustry Association (BIA), a trade association for innovative enterprises involved in U.K. bioscience, said, “This well researched report by George Freeman is right to point out that the E.U. is seen as an enlightened and progressive region for investing in biomedical research and that E.U. membership gives U.K.-based life science companies access to the single market and a uniform regulatory system for the development and approval of therapies.

“Indeed, this U.K. government has shown leadership and influence on the recent important issues, like the negotiation for the draft E.U. Clinical Trials Regulation and ensuring the Unitary Patent Court for Life Sciences is housed in London,” said Bates.

“The report is right to identify that through its presence in the E.U. institutions, the U.K. is able to exert some influence over both E.U. and global rules, although it has not always done so successfully,” he said. “We support the report’s call for more effective influence from the U.K. within the E.U. to shape the E.U.’s response to new technologies.”

“The U.K. life science ecosystem needs effective advocacy in Europe to counter the anti-biotechnology interests and protectionist attitudes found in parts of the E.U., especially if we are to develop world-class businesses of the future in areas like cell therapies,” said Bates. “This is only possible from within the E.U.”

“However, the U.K. government need not look to Brussels to boost the life science sector in the U.K.,” he concluded. “It could help life sciences companies in the U.K. by introducing a fully-funded early access to medicines scheme (which is within national competence). This policy was included in its own Strategy for U.K. Life Science two years ago and which has been developed and recommended by the MHRA’s Expert Group on Innovation in the Regulation of Healthcare.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing